Regen Bio provides an update on IND

Bio-Matrix Scientific Group (BMSN +70.8%) subsidiary Regen BioPharma provides an update on its follow up on the FDA's issues regarding its HemaXellerate IND. On March 6, 2014 the company submitted a protocol modification, additional details on manufacturing, new data on the therapeutic effects of HemaXellerate I in animal models of diseases similar to aplastic anemia in humans and additional safety data to the FDA.

The agency accepted the clinical protocol and product manufacturing information but requested clarification on the animal safety studies.

On May 9, the company updated the IND and submitted it to the FDA for review.

Comments (2)
  • Mickey45
    , contributor
    Comments (11) | Send Message
    Stay tunes for the next update in the distant further of somethings like the drug Hema fails miserably,Hell most drugs pass no a days doesn`t matter about side effects look what we have out there now side effects like sudden death might occur u might go blind etc etc
    27 May 2014, 04:03 AM Reply Like
  • Mickey45
    , contributor
    Comments (11) | Send Message
    Where does all the money go to when all the money for Cancer research go to?How many people think they are looking for a cure for Cancer?
    27 May 2014, 04:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs